Kornimate/medical-research-clean huggingface dataset:
endoscopic hemostatic and sedative treatment of esophageal and gastric variceal bleeding

Conditions: Endoscopic Hemostasis; Sedation

Summary: remazolam besylate was used for sedation during endoscopic hemostasis in patients with esophageal and gastric varices rupture and bleeding in liver cirrhosis. the onset time, recovery time and incidence of adverse reactions were observed.

esophagogastric variceal bleeding (egvb) is one of the most serious and common complications of liver cirrhosis. endoscopic hemostasis is the most widely used and important method for the prevention and treatment of egvb. the treatment of varicose veins hemostasis under gastroscope has the problem of long operation time. patients are prone to nausea, vomiting and excessive secretions due to nervousness and fear, which affect endoscopic insertion and observation, leading to failure of ligation and massive bleeding, and even death. therefore, appropriate analgesic and sedative drugs are necessary to ensure endoscopic treatment and improve the prognosis. remimazolam, an ultra-short-acting benzodiazepine drug, is obtained by introducing metabolizable methyl propionate side chain into midazolam. it may have a good effect on sedation during endoscopic hemostasis in cirrhotic patients with ruptured esophageal and gastric varices.

Eligibility criteria:
inclusion criteria: * patients diagnosed with bleeding from ruptured esophageal and gastric varices * endoscopic hemostatic treatment was performed * body mass index(bmi)18～28kg/m2 exclusion criteria: * history or evidence of increased risk of sedation/anesthesia; * pregnant and lactating women; * have participated in other drug trials within 30 days prior to enrollment; * those with contraindications to propofol, opioids and their remedies; * unwilling to sign informed consent.
digital community to improve health in rural areas

Conditions: HIV Infections; Hepatitis C Virus Infection

Summary: the study is a cluster randomized controlled trial developed in counties located in appalachia and the midwest. we will prioritize counties from states with high risk for hiv and hcv infection associated with injection drug use.

the study will randomize clusters with groups of participants to an intervention or a standard of care condition.

Eligibility criteria:
inclusion criteria: * lives in target zip codes * half not using illicit substances (not including marijuana) currently or in the past * half using illicit substances (not including marijuana) currently or in the past exclusion criteria: * under the age of 18 * not in target zip codes
loiasis cross-reactive antigenemia and treatment-related adverse events

Conditions: Loiasis

Summary: this study seeks to determine which loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

a cohort of up to 50 participants with loa loa microfilarial levels between 5,000 and 18,000 per ml/blood will be treated with ivermectin in an inpatient setting. participants will be monitored for treatment-related adverse events for seven days post-treatment, and will have blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load, cytokine, and antigen levels.

Eligibility criteria:
inclusion criteria: * loa loa blood microfilariae of between 5,000 - 18,000 per ml exclusion criteria: * known allergy to ivermectin; severe comorbidities
transversal, controlled and not randomized study, laying on the desire of children and eating disorders in a population of infertile women

Conditions: Infertility; Eating Disorders

Summary: in france , 15% of couples seek help for problems conceiving . in 10% of cases, infertility remains " unexplained" . among the causes of female infertility , there are the eating disorders, as well as sexual disorders , these two cases may be linked. in addition, data from the literature seem to suggest that beyond a diagnosis of eating disorders, the feeding behavior of infertile women is more often disturbed than the general population. moreover, the notions of desire for a child and maternal representations seem essential to address in the comprehensive care of women with infertility but also tca integrating all conflicting issues reactivated at the time of motherhood. however, little work has been done on this subject. thus, we propose a study on the desire for children and the eating disorders to infertile women, to update epidemiological data, but also to better characterize this particular patient population. perspectives of this work are to improve screening measures and support through a joint work of doctors reproductive and psychiatrists.


Eligibility criteria:
inclusion criteria: * women * major * in a relationship * infertile (who criteria) * consultant in the department of infertility (bmdr) for amp * understanding of french, literate * agree to participate in the study exclusion criteria: * man * minor * pregnancy at the time of assessment * exclusive infertility spouse * disorders of higher functions (severe cognitive impairment or confusion) or psychosis (hallucinations, delusional syndrome) * major protected

Keywords: infertility desire for children eating disorder anorexia nervosa bulimia nervosa eating disorders not otherwise specified
clinic-based intervention to promote cervical cancer prevention behaviors

Conditions: Cervical Cancer

Summary: the project is a clinical behavioral research project based at university of pennsylvania. the goal of this research is to design a brief clinic-based, nurse practitioner-guided, and theory-based health promotion intervention to enhance cervical cancer prevention among young women ages 18-26 living in economically disadvantaged urban communities. the investigators will evaluate the intervention for feasibility, acceptability and preliminary efficacy.


Eligibility criteria:
inclusion criteria: * age 18-26 years * not yet received the hpv vaccine * speak, read, and understand 5th grade level of english; * had vaginal sex with a male partner in the past 2 months. exclusion criteria: • currently pregnant and/or plan to be pregnant in next 6 months

Keywords: cervical cancer prevention
clinical trial for a outpatient clinical management for complicated acute appendicitis

Conditions: Acute Appendicitis; Appendicitis Perforated; Appendicitis Suppurative

Summary: the aim of this study is to evaluate the safety and efficacy of outpatient management of complicated acute appendicitis. for this purpose, a randomized clinical trial was designed. selected patients who have undergone surgery for acute appendicitis are randomized into two groups. one group with hospitalization and another group without admission.

the aim of this study is to evaluate the efficacy and safety of outpatient management of laparoscopic appendicectomy in complicated acute appendicitis. this was a single center randomized controlled clinical trial consisting in 2 treatment groups. patients were recruited in university hospital of tarragona joan xxiii of spain. all patients admitted in the emergency department at university hospital of tarragona joan xxiii with acute appendicitis diagnosis were likely to enter in the study. all patients who met the inclusion criteria and none of the exclusion criteria were admitted to the study for emergency surgery. in order to avoid the biases a unique anesthetic and surgical protocol were established for both groups. once laparoscopic appendicectomy was performed the patients were randomly assigned to the hospitalization group or outpatient group. patients in the hospitalization group were admitted in the hospitalization ward. patients in the outpatient group were referred to the day-surgery unit where they were discharged according to aldrete criteria. the primary endpoint was the length of hospital stay (lhs). the length of hospital stay was calculated from the day and hour of admission in the surgical area to the day and hour of discharge, based on the hours of hospital stay. secondary endpoints included the failures of the outpatient management, readmissions and the hospitals cost

Eligibility criteria:
inclusion criteria: * patients over 18 years old * asa classification (american society of anesthesiologists) less than or equal to 3 * patients who live accompanied in a home at a maximum distance of 30 minutes from the hospital and an adequate cognitive capacity. exclusion criteria: * pregnancy or breastfeeding * complicated acute appendicitis * surgical management performed in more 90 minutes
continuous femoral block with levobupivacaine 0.125% or ropivacaine 0.2% in elderly patients with femoral fractures

Conditions: Femur Fracture; Hip Fractures

Summary: this study evaluates the continuous femoral block between levobupivacaine 0.125% and ropivacaine 0.2% in patients with proximal femoral fracture.these patients will be divided into 2 groups of 35 patients, one l group (levobupivacaine 0.125%) and one r group (ropivacaine 0.2%) distributed randomly, receiving continuous infusion through patient controlled analgesia (pca) pump with the following parameters: infusion 5 ml / h, bolus 5 ml, lockout 30 min.

pain is associated with neurohormonal stress, myocardial ischemia and delayed mobilization, thus being able to increase the hospitalization time and associated with increased postoperative mortality. regional anesthesia through simple or continuous femoral nerve block are options for analgesia in patients with femoral fracture, as well as analgesia by venous opioids. a potential benefit of regional anesthesia is precisely to avoid the use of opioids and other general anesthetics, which in turn are also closely related to postoperative delirium. continuous femoral block, since the preoperative period, is associated with the reduction of acute pain and opioid consumption, in patients with femoral neck fractures. there are few studies available in the literature comparing analgesic equipotency between levobupivacaine and ropivacaine in peripheral nerve blocks. in none of them, the peripheral analgesia in the femoral nerve, for proximal femoral fracture was compared.

Eligibility criteria:
inclusion criteria: * 70 years old or more * patients with femur fracture * physical status risk american society of anesthesiologists (asa) p1 - p3 exclusion criteria: * physical status asa p4 * patients with bmi \> 35 * systemic infection * injury or infection at the site of installation of the femoral perineural catheter * catheter displacement of the perineural site * montreal cognitive assessment (moca) \< 26 * patients operated before 24 hours of hospital admission

Keywords: analgesia continuous femoral block
feasibility and acceptability of hcv treatment in pregnancy

Conditions: Hepatitis C; Pregnancy Complications

Summary: pregnant adults over the age of 18 who are seen in the washington university obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to bjh with hepatitis c virus infection who have a history of past or current drug use participant duration: approximately 1 year. aims: aim 1 - evaluate adherence and treatment completion rates when glecaprevir-pibrentasvir is started during pregnancy for women who use drugs. aim 2 - evaluate patient experience with hepatitis c virus treatment during pregnancy.

pregnant adults over the age of 18 with a history of either past or current drug use who are seen in the washington university obstetrics and gynecology, maternal fetal medicine or infectious diseases clinic or admitted to bjh with hepatitis c virus infection who consent to participate in the study will be treated with glecaprevir-pibrentasvir. all consented individuals will participate in four (4) in-person study visits. at the first in-person study visit, patients will receive information about hepatitis c virus treatment, complete testing for hiv and hbv and be assessed for cirrhosis. patients who meet study criteria will initiate hcv treatment with glecaprevir-pibrentasvir. patients will return for a second in-person study visit while on hcv treatment (between day 14-56) at which time they will complete a questionnaire about medication adherence and have hcv rna testing performed. a third in-person study visit will occur at completion of hcv treatment at which time patients will again complete a questionnaire about medication adherence, and have hcv rna testing performed. the final study visit will occur 4 weeks after completion of hcv treatment at which time patients will have hcv rna testing performed. all labs that are included as part of the study are standard of care labs for all pregnant women, and are standard of care during hcv treatment (hcv rna, cbc and cmp). additional information about the clinical course of infection (including hcv rna testing obtained at the time of labor and delivery), and maternal and fetal outcomes will be abstracted from the medical record at 1 year post study enrollment. all participants will be followed longitudinally in the medical record to ascertain maternal and fetal outcomes and hcv re-infections for up to 1 year post study enrollment.

Eligibility criteria:
inclusion criteria: * female patients ≥ 18 years old, pregnant at the time of study intake, diagnosed with hepatitis c virus infection and a history of past or current drug use. exclusion criteria: -
splinting versus casting for type i supracondylar fractures

Conditions: Bone Fractures

Summary: elbow fractures are very common in young children. type i supracondylar fractures are stable fractures to the elbow that are treated conservatively across the world and typically heal very well without complications. there are several treatment options, including an above elbow cast or long arm splint. this study aims to determine if one treatment is no worse than the other in order to standardize the treatment of these fractures at our institution. the investigators hope to save families from extra hospital visits and reduce the amount of x-rays required for treatment of these fractures.


Eligibility criteria:
inclusion criteria: * ages 3-12 * type 1 supracondylar fracture exclusion criteria: * a type 2 or 3 supracondylar fracture * neurovascular compromise associated with the fracture * previous diagnosis with a metabolic or structural bone disease * other fractures to ipsilateral upper extremity * history of injury to affected elbow

Keywords: fracture supracondylar pediatric orthopedic
acupressure mat on perceived stress, sleep quality and premenstrual symptoms

Conditions: Premenstrual Symptoms; Effect of Acupressure Mat

Summary: purpose of the study: to examine the effect of acupressure mat on perceived stress, sleep quality and premenstrual symptoms in students with premenstrual syndrome. hypotheses of the study; in the post-test and follow-up test between students who were applied acupressure mat and those who were applied plain mat; h10: there is no difference in terms of severity of premenstrual symptoms. h20: there is no difference in terms of perceived stress. h30: there is no difference in terms of sleep quality.


Eligibility criteria:
inclusion criteria: * using medication and/or non-medical methods to cope with pms * having any gynecological disease (abnormal uterine bleeding, myoma, ovarian cyst, etc.) * using contraceptive medication. exclusion criteria: * participants wanting to withdraw from the study at any stage of the study * participants not complying with the research plan * diagnosed with a psychiatric or gynecological disease during the study * participants starting to receive additional treatment for pms during the study period
clinical study evaluating efficacy, safety and molecular mechanism of n-acetylcysteine supplementation in patients with hepatic and post hepatic jaundice

Conditions: Hepatic and Post Hepatic Jaundice

Summary: investigating the efficacy, safety, and molecular mechanism of n-acetylcysteine supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice.


Eligibility criteria:
inclusion criteria: * patients age 18-70 years old. * patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dl. exclusion criteria: * pregnancy. * nursing mothers. * patients with increased indirect bilirubin level. * patients who have gilbert syndrome or crigler najjar syndrome. * patients with child paugh c score (10-15 point). * history of known hypersensitivity to n-acetylcysteine.

Keywords: jaundice n-acetylcysteine tac tnf-α bilirubin
non-phonatory exercises in patients with unilateral vocal fold paralysis post-thyroidectomy

Conditions: Unilateral Vocal Cord Paralysis

Summary: thyroidectomy is the most common iatrogenic cause of vocal fold paralysis. patients complain of hoarseness caused by incomplete glottic closure and have effort to raise vocal intensity with consequent elevation of the larynx and/or involvement of supraglottic structures in phonation. these compensation mechanisms result in a shift of the fundamental frequency towards more serious tones or falsetto voice emissions. the first choice treatment is speech therapy which aims to obtain better glottic closure, preventing ankylosis of the crico-arytenoid joint. in order to promote better glottic closure without risking the onset or increase of dysfunctional compensation, the idea behind this project is to propose non-phonatory adduction exercises in the first post-operative week. the primary objective of the study is to compare patients who will perform non-phonatory exercises in parallel with medical therapy for one week and patients who will perform standard medical therapy only during the first week.


Eligibility criteria:
inclusion criteria: * vocal fold paralysis after thyrodectomy * ability to sign an informed consent exclusion criteria: * vocal fold paralysis with different etiology * previous history of laryngeal, pulmonary or gastric surgery * history of vocal or laryngeal pathologies that have required therapy * current or previous lung disorders * hearing loss * motor or neurological deficits * presence of malignant diseases * presence of speech or reading disorders
clinical evaluation of the antibacterial activity of thioglycosides extracted from white mustard - bamberka in oral hygiene. evaluation of periodontal parameters and oral microbiota in patients.

Conditions: Gingival and Periodontal Disease; Caries, Dental

Summary: brief summary the goal of this randomized clinical trial is to evaluate the clinical and antibacterial effects of a herbal toothpaste containing white mustard (sinapis alba) extract in patients diagnosed with gingivitis. the main questions it aims to answer are: does the herbal toothpaste significantly reduce plaque index (pi), approximal plaque index (api), gingival index (gi), and bleeding on probing (bop) compared to a placebo toothpaste? does the herbal toothpaste effectively reduce the bacterial loads of streptococcus mutans and lactobacillus spp. in saliva compared to a placebo? researchers will compare the effects of the herbal toothpaste to a placebo toothpaste to determine its efficacy in improving periodontal parameters and reducing bacterial levels. participants will: be randomly assigned to one of two groups: test group (herbal toothpaste) or control group (placebo toothpaste). use the assigned toothpaste twice daily for 4 weeks. undergo clinical evaluations at baseline (t0) and after 4 weeks (t1), including measurements of pi, api, gi, and bop. provide saliva samples at t0 and t1 for microbiological analysis of streptococcus mutans and lactobacillus spp. bacterial loads.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years, * the presence of at least 20 teeth excluding third molars, * a diagnosis of gingivitis according to the 2017 world workshop * non-smokers. * the motivation to take part in the study, * proper oral home hygiene * sign a consent agreement for the participation in the study exclusion criteria: * patients aged \<18 * the presence of less than 20 teeth * severe systemic diseases and diseases that require regular systemic drugs (diabetes mellitus) * the use of systemic antibiotics during the last 3 months or local antiseptics that may affect biofilm formation (antibacterial mouth rinses containing chlorhexidine 4 weeks or less prior recruitment) * allergy to mustard or any other compound of experimental toothpaste * patients undergoing orthodontic treatment * women who were pregnant or breastfeeding.

Keywords: caries. thioglycosides periodontitis gingivitis lactobacillus toothpaste mustard
safety and immunogenicity of chiron's investigational h. pylori vaccine in healthy adults

Conditions: Helicobacter Pylori; Gastritis; Gastric Cancer; Gastroduodenal Ulcers; Lymphoma

Summary: this study was designed to investigate the safety and immunogenicity of chiron's investigational h. pylori (hp3) vaccine


Eligibility criteria:
inclusion criteria: * healthy * ages 18-40 * negative for h. pylori infection * contraception for females exclusion criteria: * present or past h. pylori infection * medically significant gastroduodenal disease * recent corticosteroid use * bleed diathesis * use of antibiotics used to treat h. pylori infection
serratus plane block and pectointercostal block

Conditions: Postoperative Pain

Summary: asa i-ii female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. patients will divide into 2 groups. deep serratus plane block will perform with 0,25 %bupivacaine 20 ml at the midaxillary 5. rib, bilaterally for group i. at group ii, deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally . general anesthesia with sevoflurane and remifentanil will perform to the all patients. postoperative pain scores, morphine consumption and complications will record till the 24.th hours.

asa i-ii female patients aged over 18 who will undergoing breast reduction surgery will recruit to the study. general anesthesia with sevoflurane and remifentanil will perform to the all patients. patients will divide into 2 groups. serratus plane block for group i and serratus plane block+pectointercostal block for group ii will perform bilaterally. ultrasound guided deep serratus plane block will perform with 0,25% bupivacaine 20 ml at the midaxillary 5. rib, for group i. at group ii, ultrasound guided deep serratus plane block ( 0,25 %bupivacaine 20 ml) at the midaxillary 5.th rib+ pectointercostal plane block (0,25% bupivacaine 15 ml) at 4-5.th intercostal space will perform bilaterally. patient controlled analgesia will perform with morphine ( 1 mg bolus+ 10 min lockout+4 hours limit 10 mg) at postoperative period. patients will evaluate with visual analogue scale (vas) for postoperative pain scores till the first 24.th hours. postoperative pain scores (vas), morphine consumption and complications will record till the 24.th hours.

Eligibility criteria:
inclusion criteria: * asa i-ii patients * female * who will undergoing breast reduction surgery exclusion criteria: * asa iii and over patients * who reject to join the study * male gender